| Immunotherapy for melanoma AA Albittar, O Alhalabi, IC Glitza Oliva Immunotherapy, 51-68, 2020 | 53 | 2020 |
| Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy A Zarifa, A Albittar, PY Kim, S Hassan, N Palaskas, C Iliescu, JB Durand, ... Current opinion in cardiology 34 (4), 441-450, 2019 | 20 | 2019 |
| Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study A Sheshadri, AA Goizueta, VR Shannon, D London, G Garcia‐Manero, ... Cancer 128 (14), 2736-2745, 2022 | 7 | 2022 |
| Incidence and risk factors for pneumonitis associated with checkpoint inhibitors in advanced non-small cell lung cancer: a single center experience M Altan, F Soto, LL Zhong, FO Akhmedzhanov, NR Wilson, A Zarifa, ... The Oncologist 28 (11), e1065-e1074, 2023 | 4 | 2023 |
| Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL EC Liang, A Albittar, JJ Huang, AV Hirayama, EL Kimble, AJ Portuguese, ... Blood Advances 7 (22), 6990-7005, 2023 | 3 | 2023 |
| Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study R Dev, LL Zhong, A Zarifa, AA Albittar, L Rubin, S Liu, TA Yap, S Dalal, ... Investigational New Drugs, 1-10, 2022 | 3 | 2022 |
| Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases O Alhalabi, Z Soomro, R Sun, E Hasanov, A Albittar, D Tripathy, V Valero, ... NPJ Breast Cancer 7 (1), 28, 2021 | 3 | 2021 |
| Transplantation for myeloid neoplasms with antecedent solid tumor AJ Portuguese, A Albittar, TH Gooley, HJ Deeg Cancer 129 (1), 142-150, 2023 | 2 | 2023 |
| Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity EC Liang, K Rejeski, T Fei, A Albittar, JJ Huang, AJ Portuguese, Q Wu, ... Bone Marrow Transplantation, 1-8, 2024 | 1 | 2024 |
| P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL E Liang, A Hirayama, E Kimble, A Portuguese, A Albittar, A Chapuis, ... HemaSphere 7 (S3), e472395b, 2023 | 1 | 2023 |
| Systemic therapy for patients with breast cancer and one to three brain metastases (BM). ZA Soomro, O Alhalabi, R Sun, A Albittar, L Hsu, V Valero, NK Ibrahim Journal of Clinical Oncology 38 (15_suppl), 1090-1090, 2020 | 1 | 2020 |
| Human Herpesvirus-6 Reactivation and Disease Are Infrequent in Chimeric Antigen Receptor T-cell Therapy Recipients E Kampouri, EM Krantz, H Xie, SS Ibrahimi, ES Kiem, MK Sekhon, ... Blood Journal, blood. 2024024145, 2024 | | 2024 |
| Safety and Efficacy of Fully-Human-Binder-Bearing CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma after Failure of Murine-Binder-Bearing CD19 CAR T-Cell Therapy JJ Huang, AV Hirayama, CA Jaeger-Ruckstuhl, EC Liang, A Albittar, ... Transplantation and Cellular Therapy 30 (2), S186, 2024 | | 2024 |
| T-Cell Large Granular Lymphocyte Population Involving Chimeric Antigen Receptor-Modified T (CAR T) Cells in Patients with Cytopenia after CD19-Targeted CAR T-Cell Therapy: Case … A Albittar, A Torabi, EC Liang, AJ Portuguese, JJ Huang, C Yeung, ... Transplantation and Cellular Therapy 30 (2), S176, 2024 | | 2024 |
| Planned Interim Analysis of a Phase 2 Investigator-Initiated Trial of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel EC Liang, A Albittar, AJ Portuguese, JJ Huang, N Wuliji, Q Wu, ... Transplantation and Cellular Therapy 30 (2), S179-S180, 2024 | | 2024 |
| Identification and Prediction of Severe Hematologic Toxicity after CAR T-Cell Therapy Using Machine Learning-Based Time-Series Clustering EC Liang, A Albittar, AJ Portuguese, JJ Huang, N Wuliji, Q Wu, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
| Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & Toxicity AJ Portuguese, A Albittar, JJ Huang, EC Liang, N Wuliji, M Taheri, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
| Early Prediction of Severe Icans after CD19 CAR T-Cell Therapy Based on Serum Ferritin Levels JJ Huang, EC Liang, A Albittar, AJ Portuguese, N Wuliji, A Torkelson, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
| Risk Factors for Pre-CAR-T Attrition Among Large B-Cell Lymphoma (LBCL) Patients N Wuliji, R Banerjee, EC Liang, JJ Huang, A Albittar, M Taheri, M Durbin, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
| Identification of Predictors of CRS and Neurotoxicity Duration after Axicabtagene Ciloleucel Therapy A Albittar, JM Voutsinas, AJ Portuguese, JJ Huang, EC Liang, N Wuliji, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
